Raphael Pharmaceutical (RAPH) Equity Average (2020 - 2025)

Raphael Pharmaceutical has disclosed Equity Average across 6 years of filings, most recently posting -$1.3 million for Q4 2025.

• Equity Average for Q4 2025 came in at -$1.3 million, down 98.6% year-over-year; the trailing twelve-month figure through Dec 2025 was -$1.3 million (down 98.6% YoY), and the FY2025 annual result was -$1.1 million, down 242.52% from the prior year.
• Equity Average came in at -$1.3 million for Q4 2025 at Raphael Pharmaceutical, down from -$1.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $115500.0 in Q1 2022 to a low of -$1.3 million in Q4 2025.
• The 5-year median for Equity Average is -$44250.0 (2021), against an average of -$270600.0.
• Across the five-year window, Equity Average soared 1366.67% in 2022 and plunged 37000.0% in 2025, its largest moves.
• Raphael Pharmaceutical's Equity Average stood at $1500.0 in 2021, then jumped by 1366.67% to $22000.0 in 2022, then fell by 27.27% to $16000.0 in 2023, then slumped by 4343.75% to -$679000.0 in 2024, then plunged by 98.6% to -$1.3 million in 2025.
• The last three Equity Average figures came in at -$1.3 million (Q4 2025), -$1.2 million (Q3 2025), and -$891000.0 (Q2 2025), per Business Quant data.